FyMed Expands Its Discovery and Drug Development Plans Through Innovative Strategies in Precision Medicine
20/09/15 02:21 Filed in: expansions | pharmaceutical company | biotechnology company | precision medicine | drug discovery
FyMed, Inc. today announced strategic and operational expansion plans following the successful completion of major preclinical drug studies utilizing innovative companion diagnostic and prognostic technologies in precision medicine.
Read More...
Read More...
FyMed Announces Notice of Allowance for US Patent Covering Fy10 Technology Platform
15/05/15 09:00 Filed in: patent | drug discovery | precision medicine | anti-inflammatory | immunomodulatory | Novel | FY10
FyMed Inc., a specialty pharmaceutical company focused on the development and commercialization of novel therapeutics announced that its application covering the Fy10 technology platform was allowed for issuance as a new patent by the USPTO. Read More...
Early Release: FyMed Gets Patent for Novel Immunomodulatory Drug
Pharmaceutical firm FyMed Inc. has received a patent for a novel immunomodulatory drug used in the treatment of autoimmune diseases.
Read More...
Read More...
FyMed Heralds Breakthrough in the Treatment of Colon Cancer with Novel Drug Candidate FY405B
16/02/15 08:00 Filed in: innovations | drug discovery | pharmaceutical company | cancer | FY405B | superior | colon
Scientists at FyMed, Inc. have identified a novel drug target in the management of colon cancer, developing a candidate that has shown significant promise for the treatment of this difficult-to-treat disease in early studies. Read More...